Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionShelton Capital Management
Latest Disclosed Ownership36,379 shares
Latest Disclosed Value $ 16,244,679
Shelton Capital Management reports 2.31% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Shelton Capital Management filed a 13F-HR form disclosing ownership of 36,379 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $16,244,679 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 37,241 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -2.31% during the quarter. The current value of the position is $16,255,229 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 36,379 -862 -2.31 16,245 -3.78 0.3553
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 37,241 562 1.53 16,884 17.54 0.3333
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 36,679 -16,336 -30.81 14,365 -39.14 0.3076
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 53,015 -336 -0.63 23,602 -8.75 0.5430
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 53,351 -1,280 -2.34 25,866 17.57 0.6162
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 54,631 647 1.20 22,000 -12.38 0.5475
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 53,984 6,276 13.16 25,107 12.28 0.6446
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 47,708 230 0.48 22,362 12.67 0.6071
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 47,478 4,354 10.10 19,846 13.11 0.5635
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,124 12,821 42.31 17,547 66.52 0.5555
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 30,303 6,534 27.49 10,538 25.98 0.3860
2023-08-10 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,769 907 3.97 8,365 16.12 0.3003
2023-05-11 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 22,862 2,614 12.91 7,203 23.19 0.3000
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 20,248 -4,854 -19.34 5,847 -19.55 0.6124
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,102 344 1.39 7,268 4.17 0.3456
2022-08-11 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,758 0 0.00 6,977 7.99 0.3138
2022-05-12 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,758 481 1.98 6,461 21.20 0.2386
2022-02-11 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,277 477 2.00 5,331 23.49 0.1887
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,800 -8,400 -26.09 4,317 -33.50 0.1687
2021-08-12 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,200 0 0.00 6,492 -6.17 0.2450
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 32,200 10,388 47.63 6,919 34.22 0.2408
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,812 0 0.00 5,155 -13.14 0.2316
2020-11-09 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 21,812 0 0.00 5,935 -6.27 0.2457
2020-08-12 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 21,812 234 1.08 6,332 23.33 0.3488
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,578 -377 -1.72 5,134 6.80 0.3721
2020-02-11 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,955 -731 -3.22 4,807 25.08 0.2657
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 22,686 -3,366 -12.92 3,843 -19.55 0.2268
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,052 21,601 485.31 4,777 -80.26 0.2752
2019-05-10 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,451 -19,744 -81.60 24,195 503.52 0.0954
2019-01-31 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,195 0 0.00 4,009 -14.03 0.2727
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,195 0 0.00 4,663 13.40 0.2659
2018-08-10 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,195 -1,000 -3.97 4,112 0.15 0.2558
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,195 2,122 9.20 4,106 18.74 0.2693
2018-02-06 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,073 0 0.00 3,458 -1.43 0.2221
2017-11-28 2017-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 23,073 0 0.00 3,508 18.00 0.2368
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,073 0 3,508
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,073 5,111 28.45 2,973 51.37 0.2101
2017-11-28 2017-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 17,962 1,000 5.90 1,964 57.12 0.1360
2017-05-15 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,462 14,500 3,440
2017-11-28 2016-12-31 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 16,962 0 0.00 1,250 -15.48 0.0952
2017-02-16 2016-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 16,962 0 1,250 0.1097
2017-12-06 2016-09-30 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 16,962 0 0.00 1,479 1.37 0.1234
2017-12-04 2016-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 16,962 0 1,250 0.0797
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,962 0 1,479
2016-08-01 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,962 -962 -5.37 1,459 2.39 0.1286
2016-05-13 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,924 1,678 10.33 1,425 -30.28 0.1290
2016-02-01 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,246 701 4.51 2,044 26.25 0.1976
2015-11-02 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,545 2,517 19.32 1,619 0.62 0.1782
2015-08-11 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,028 -897 -6.44 1,609 -2.07 0.1664
2015-05-12 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,925 2,359 20.40 1,643 19.58 0.1775
2015-02-10 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,566 1,994 20.83 1,374 27.81 0.1600
2014-10-15 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,572 1,007 11.76 1,075 32.55 0.1445
2014-07-25 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,565 1,725 25.22 811 67.56 0.1132
2014-04-14 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,840 760 12.50 484 7.08 0.0710
2014-01-22 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,080 -22,141 -78.46 452 -78.88 0.0684
2013-10-16 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,221 248 0.89 2,140 -4.21 0.3580
2013-07-10 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 27,973 27,973 2,234 0.4076
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.